Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 1;33(6):387-393.
doi: 10.1097/IJG.0000000000002387. Epub 2024 Mar 28.

Metformin in Glaucoma Treatment

Qëndresë Daka  1   2 , Burim Neziri  1 , Ewald Lindner  3 , Augusto Azuara Blanco  4
Affiliations
Review

Metformin in Glaucoma Treatment

Qëndresë Daka et al. J Glaucoma. .

Abstract

Prcis: Rigorous trials are essential to develop comprehensive treatment strategies that fully exploit the therapeutic potential of metformin in the treatment of glaucoma.

Objective: The objective of this study was to evaluate the potentially beneficial effect of metformin on glaucoma risk factors and to investigate the underlying mechanisms. The aim is to contribute to the development of new treatment strategies for glaucoma.

Methods: We searched for studies that assessed the effects of metformin on glaucoma risk factors and the associated underlying mechanisms. Our search included electronic databases such as PUBMED, EMBASE, and clinicaltrials.gov.

Results: Unfortunately, we did not find any clinical trials that specifically investigated the impact of metformin on glaucoma. However, data from experimental studies demonstrated the capability of metformin to modulate various pathways that could contribute to neuroprotection in glaucoma.

Conclusion: In order to develop comprehensive treatment strategies that fully exploit the therapeutic potential of metformin in the treatment of glaucoma, rigorous trials are essential. These studies are necessary to demonstrate both the safety and efficacy of metformin in the context of glaucoma treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors declare no conflict of interest.

References

    1. Bourne RR, Taylor HR, Flaxman SR, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990-2010: a meta-analysis. PLoS One. 2016;11:e0162229.
    1. Hurley DJ, Irnaten M, O’Brien C. Metformin and glaucoma-review of anti-fibrotic processes and bioenergetics. Cells. 2021;10:2131.
    1. Daka Q, Azuara-Blanco A Angle-Closure Glaucoma: Epidemiology, Pathophysiology and Clinical Impact – book chapter Ed. Gillmann, Mansouri. The Science of Glaucoma Management. 2023;105–114.
    1. Daka Q, Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croat Med J. 2014;55:468–480.
    1. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.

MeSH terms